Limited English Proficient Patients and Time Spent in Therapeutic Range in a Warfarin Anticoagulation Clinic

Fatima Rodriguez, MD, MPH; Clemens Hong, MD, MPH; Yuchiao Chang, PhD; Lynn B. Oertel, MS, ANP; Daniel E. Singer, MD; Alexander R. Green, MD, MPH; Lenny López, MD, MPH, MDiv

Background—While anticoagulation clinics have been shown to deliver tailored, high-quality care to patients receiving warfarin therapy, communication barriers with limited English proficient (LEP) patients may lead to disparities in anticoagulation outcomes.

Methods and Results—We analyzed data on 3770 patients receiving care from the Massachusetts General Hospital Anticoagulation Management Service (AMS) from 2009 to 2010. This included data on international normalized ratio (INR) tests and patient characteristics, including language and whether AMS used a surrogate for primary communication. We calculated percent time in therapeutic range (TTR for INR between 2.0 and 3.0) and time in danger range (TDR for INR <1.8 or >3.5) using the standard Rosendaal interpolation method. There were 241 LEP patients; LEP patients, compared with non-LEP patients, had a higher number of comorbidities (3.2 versus 2.9 comorbidities, \(P=0.004\)), were more frequently uninsured (17.0% versus 4.3%, \(P=0.001\)), and less educated (47.7% versus 6.0% ≤ high school education, \(P=0.001\)). LEP patients compared with non-LEP patients spent less TTR (71.6% versus 74.0%, \(P=0.007\)) and more TDR (12.9% versus 11.3%, \(P=0.018\)). In adjusted analyses, LEP patients had lower TTR as compared with non-LEP patients (OR 1.5, 95% CI [1.1, 2.2]). LEP patients who used a communication surrogate spent less TTR and more TDR.

Conclusion—Even within a large anticoagulation clinic with a high average TTR, a small but significant decrease in TTR was observed for LEP patients compared with English speakers. Future studies are warranted to explore how the use of professional interpreters impact TTR for LEP patients. (J Am Heart Assoc. 2013;2:e000170 doi: 10.1161/JAHA.113.000170)

Key Words: adverse drug events • limited English proficiency • outcomes research • quality of care • warfarin

The United States is increasingly diverse with growing populations of racial and ethnic minorities and immigrants, many of whom have difficulty communicating in English. According to recent estimates, over 55 million Americans, or 20% of the total population, speak a language other than English at home.\(^1\) Of these individuals, over half self-report speaking English less than “very well” and are considered to have Limited English Proficiency (LEP).\(^2\)

Patients with communication problems due to language barriers are at high risk for preventable adverse events.\(^3–7\) Similarly, drug complications in outpatients are more common in patients who speak a primary language other than English.\(^8\)

Warfarin, a commonly prescribed anticoagulant, has a narrow therapeutic range and therefore requires frequent, long-term monitoring and close communication between patients and providers. Warfarin is indicated for patients with atrial fibrillation and venous thromboembolism in order to prevent ischemic stroke and other adverse outcomes.\(^9,10\) Low literacy levels and limited English proficiency have been associated with poor anticoagulation control.\(^11–14\) Monitoring time in therapeutic range (TTR) can serve as an indicator of the quality of anticoagulation and a surrogate for markers of anticoagulation complications.\(^13,15–18\) Studies have demonstrated that patients who spend less time in TTR are at increased risk for serious bleeding complications, including higher risk of intracranial hemorrhage.\(^13,19,20\) To our knowledge, there have been no previous studies showing the relationship between LEP status and TTR.

Due to the proven clinical importance of high-quality warfarin control for preventing adverse outcomes, understanding how...
patients with communication barriers perform is of critical importance. Using detailed clinical data from a large anticoagulation clinic, we sought to answer 3 questions: (1) Do differences in TTR exist between LEP and non-LEP patients? (2) Are LEP patients more likely to spend time in the danger range (ie, sub- or supratherapeutic international normalized ratios [INRs]) compared with non-LEP patients? (3) Does the use of communication surrogates impact TTR? Answering these questions may have important implications for how warfarin management clinics could be organized.

Methods

Study Population

The Massachusetts General Hospital Anticoagulation Management Service (AMS) is a large, nurse-run anticoagulation service that provides comprehensive education on anticoagulation management, monitors each patient’s INR, and recommends follow-up dosing changes using standardized protocols. Both primary care physicians and specialists, from both inpatient and outpatient settings, refer patients to the AMS. Patient follow-up is based on the prescribed duration of warfarin therapy. Referring physicians complete annual therapy reviews to confirm the current treatment plan and evaluate the risks and benefits of continued therapy. AMS uses a standardized process to monitor adherence, including a series of automated reminder calls and letters to inform patients of missed INR dates. AMS regularly uses medical interpreters to collect information and deliver dosing information to patients. AMS nurses collaborate with the referring physician to promote adherence and safety and, as a result, AMS discharges few patients for nonadherence.

We linked data from the AMS with the Research Patient Data Repository (RPDR) through each patient’s unique medical number. The RPDR gathers clinical information from patients’ electronic medical records at various hospitals and stores them in a central data registry. We obtained data on patients who received care from AMS from January 1, 2009 through December 31, 2010 for all clinical indications with an INR target between 2 and 3. We collected data on English language proficiency, INR, patient sociodemographic characteristics, site of primary care, and whether or not they used a surrogate for primary communication with the providers.

Study Variables

Based on randomized trials and clinical guidelines, an INR between 2.0 to 3.0 is the standard target anticoagulation intensity for patients with atrial fibrillation or venous thromboembolism. Using each patient’s INR data, we calculated the time in therapeutic range (TTR defined as time with an INR between 2.0 and 3.0) and time in danger range (TDR defined as INR <1.8 or >3.5) for each patient using the standard Rosendaal interpolation method. Prior research has demonstrated that stroke risk for patients with AF increases markedly at INR levels below 1.8 and the risk for intracranial hemorrhage increases at INR levels above 3.5. We defined TTR as the number of person-days with an INR of 2.0 to 3.0 divided by the total number of person-days on warfarin. This is presented as the average TTR for each individual.

LEP patients were identified as those who reported speaking English less than “very well,” as self-reported in their registration documentation. Secondary predictors included self-designated use of a communication surrogate, defined as a family member or other person identified as the primary contact with whom AMS nurses communicate to manage warfarin dosing and frequency of INR monitoring. A communication surrogate is not limited to telephonic communication with AMS, but may also have broader responsibilities such as administration of warfarin, appointment transportation, and other patient medical needs.

Sociodemographic variables included age, gender, race/ethnicity (self-reported as white, Hispanic, black, Asian, other or unknown), education (less than high school, high school or GED, college, or more than college) and insurance status (commercial, Medicare, Medicaid, self-pay, or free care).

A comorbidity index based on a count of comorbid conditions was used for risk adjustment. We included comorbid conditions present at enrollment to AMS based on ambulatory billing data, as have been used by other studies. These included atrial fibrillation, chronic obstructive pulmonary disease, coronary artery disease, depression, diabetes mellitus, congestive heart failure, hypertension, osteoarthritis, or a cerebral vascular accident. This study protocol was approved by the Massachusetts General Hospital’s Institutional Review Board and informed consent was waived since we analyzed deidentified, retrospective data.

Statistical Analyses

We compared LEP and non-LEP patient characteristics using 2-sample t tests or chi-square tests. We conducted bivariate analyses to explore the associations between LEP status and outcomes using 2-sample t tests for percent time in range and chi-square tests for the percentage of patients above or below a cutoff point.

We dichotomized TTR at 65% and TDR at 15% because these levels are considered to represent adequate anticoagulation control based on data from recent clinical trials. We utilized multivariable logistic regression models to examine the relationship between LEP status and these 2 dichotomized outcomes, controlling for demographic and clinical covariates.
We repeated the regression analyses stratified by LEP status and the use of surrogates. SAS version 9.3 (SAS Institute Inc) was used for all analyses. All reported P values are 2-tailed and values <0.05 were considered statistically significant.

Results
Among 3770 total patients enrolled in the anticoagulation clinic in 2009 and 2010, the most common primary indications for anticoagulation were atrial fibrillation (68.4%) and venous thrombosis or thromboembolism (14.1%) (Table 1). There were 241 LEP patients in our sample (6.4%). LEP patients, compared with non-LEP patients, were more likely to be women (42.7% versus 30.1%, \( P = 0.002 \)), minorities (45.6% versus 5.2%, \( P < 0.001 \)), underinsured (17.0% versus 4.3% with Medicaid, free Care or self-pay, \( P < 0.001 \)), and less educated (47.7% versus 6.0% with less than a high school education, \( P < 0.001 \)), and had a higher number of comorbidities (3.2 versus 2.9, \( P = 0.004 \)).

The overall mean TTR for all patients enrolled in the AMS clinic was 73.8% (median 76.1%). The overall TDR mean was 11.4% (median 8.6%). The primary predictor of TTR was LEP status as a binary variable. In unadjusted analyses, LEP patients had a lower mean TTR than non-LEP patients (71.6% versus 74.0%, \( P = 0.007 \)) and a higher mean TDR (12.9% versus 11.3%, \( P = 0.018 \)) (Table 2). More LEP patients spent <65% of the TTR as compared with non-LEP patients (27.8 versus 20.6%, \( P = 0.008 \)). LEP patients were also more likely to spend more than 15% of total TDR as compared with non-LEP patients (32.4% versus 24.3%, \( P = 0.005 \)).

After adjusting for sociodemographic and clinical factors, LEP patients were more likely to spend less TTR (OR 1.5, 95% CI 1.1, 2.2) but were not at greater risk of spending more TDR (OR 1.3, 95% CI 0.9, 1.9) (Table 3).

A total of 585 patients (16% of the study sample) reported using a communication surrogate, representing 61.4% of LEP patients and 12.4% of the non-LEP patients. Patients who

Table 1. Study Population Characteristics (n=3770)

| Characteristic                        | LEP (n=241) | Non-LEP (n=3529) | \( P \) Value |
|--------------------------------------|------------|-----------------|--------------|
| Age, mean (SD)                       | 73.0 (13.8)| 71.5 (13.0)    | 0.12         |
| Women, %                             | 42.7%      | 30.1%           | 0.002        |
| White, %                             | 47.7%      | 89.2%           | <0.001       |
| Insurance                            |            |                 | <0.001       |
| Commercial                           | 14.9%      | 20.5%           |             |
| Medicare                             | 49.8%      | 48.4%           |             |
| Medicaid/self-pay/free care          | 17.0%      | 4.3%            |             |
| Less than high school education      | 47.7%      | 6.0%            | <0.001       |
| Comorbidity count, mean (SD)         | 3.2 (1.5)  | 2.9 (1.6)       | 0.004        |
| Surrogate, %                         | 61.4%      | 12.4%           | <0.001       |
| Indication for anticoagulation       |            |                 | 0.11         |
| Atrial fibrillation                  | 70.5%      | 68.3%           |             |
| Venous thromboembolism               | 13.7%      | 14.2%           |             |
| CVD/CAD                              | 10.0%      | 8.3%            |             |
| CHF                                  | 2.1%       | 1.4%            |             |
| Valvular disease                     | 2.1%       | 2.6%            |             |
| Other                                | 1.6%       | 5.2%            |             |

LEP indicates limited English proficiency; SD, standard deviation; CVD, cardiovascular disease; CAD, coronary artery disease; CHF, congestive heart failure.

Table 2. Time in Therapeutic Range and Time in Danger Range for LEP Versus Non-LEP Patients

| Characteristic                        | LEP       | Non-LEP    | \( P \) Value |
|--------------------------------------|-----------|------------|--------------|
| % TTR, mean (SD)                     | 71.6 (13.1)| 74.0 (13.9)| 0.007        |
| % TDR, mean (SD)                     | 12.9 (10.2)| 11.3 (11.0)| 0.018        |
| % Time INR <1.8, mean (SD)           | 9.5 (8.8) | 8.1 (9.5)  | 0.023        |
| % Time INR >3.5, mean (SD)           | 3.5 (3.5) | 3.2 (4.2)  | 0.26         |
| % of patients with TTR <65%          | 27.8      | 20.6       | 0.008        |
| % of patients with TDR >15%          | 32.4      | 24.3       | 0.005        |

LEP indicates limited English proficiency; TTR, time in therapeutic range; TDR, time in danger range; SD, standard deviation; INR, international normalized ratio.

Table 3. Multivariable Logistic Regression Models*

| Predictor                       | TTR <65%, OR (95% CI) | TDR >15%, OR (95% CI) |
|---------------------------------|-----------------------|-----------------------|
| LEP vs non-LEP                  | 1.5 (1.1, 2.2)        | 1.3 (0.9, 1.9)        |
| LEP surrogate vs non-LEP surrogate| 1.2 (0.6, 2.2)       | 1.2 (0.6, 2.2)        |
| LEP no surrogate vs non-LEP no surrogate| 1.5 (0.9, 2.6) | 1.3 (0.8, 2.3)        |
| LEP surrogate vs LEP no surrogate| 1.2 (0.6, 2.3)       | 1.2 (0.6, 2.2)        |
| LEP surrogate vs non-LEP no surrogate| 1.8 (1.1, 2.8)      | 1.6 (1.1, 2.5)        |

TTR indicates time in therapeutic range; TDR, time in danger range; OR, odds ratio; CI, confidence interval; LEP, limited English proficiency.

*Adjusted for sociodemographic (age, gender, education, insurance) and clinical factors (comorbidity counts).
used a surrogate were older (mean age 77.1 versus 70.6, \(P<0.001\)), more likely to be underinsured (7.5% versus 4.7% with Medicaid, Free Care, or Self-pay, \(P<0.001\)), and more likely to have less than a high school education (23.1% versus 6.1%, \(P<0.001\)). Additionally, these patients had a higher comorbidity count as compared with patients without a communication surrogate (3.3 versus 2.9, \(P=0.007\)). The interaction analyses for LEP and surrogate use were significant for both TTR (\(P=0.0297\)) and TDR (\(P=0.005\)). There were no significant differences among LEP patients in TTR or TDR with and without surrogate use. Both LEP and non-LEP patients who used a communication surrogate spent less TTR and more TDR, as compared with non-LEP patients who did not use a communication surrogate (Table 3). As compared with non-LEP patients without a surrogate, LEP patients who used a surrogate were more likely to spend less TTR (OR 1.8, 95% CI [1.1, 2.5]) and a greater amount of TDR (OR 1.6, 95% CI [1.1, 2.5]).

Discussion

Using data from a high-quality anticoagulation clinic, we found that patients had a high average TTR at 74%. However, LEP patients spent more time with suboptimal TTR and in TDR compared with non-LEP patients. In adjusted analyses, LEP patients spent significantly more time in subtherapeutic INR values <1.8. In addition, the use of a communication surrogate was associated with less TTR and more TDR for both LEP and non-LEP patients.

High-quality anticoagulation with warfarin demands communication with patients and close monitoring of INR levels for dose adjustment. Prior studies have documented that anticoagulation clinics improve patient outcomes, with patients provided with useful adjuncts to existing AMS services.\(^{15,41}\) Alternatively, our study suggests that LEP patients, particularly those who require a communication surrogate, may benefit from the use of newer anticoagulants that require less intensive monitoring. Future studies should explore the role of these newer anticoagulants for LEP patients who may find it particularly challenging to monitor and adjust their warfarin dosing.\(^{42,43}\)

There are several limitations to our study that warrant mention. In our study, we were unable to account for the type of surrogate used by patients or the exact communication and management role of the surrogate with LEP patients. Similarly, the use of data from a single anticoagulation clinic at an academic institution limits generalizability to other clinical settings. We were also unable to measure adverse events (ie, bleeding or stroke) associated with sub- or supratherapeutic anticoagulation. However, published studies have documented the association of suboptimal TTR with bleeding and stroke complications.\(^{13,19}\) Finally, we were unable to take into account the intensity of contact with the anticoagulation clinic during the study period.

Conclusion

Our study suggests that, overall, patients managed by a dedicated anticoagulation clinic can achieve a high average TTR. Still, a small but significant disparity exists for LEP patients, particularly those who require communication surrogates. To our knowledge, there have been no previous studies showing the relationship between LEP status and TTR.
Future studies should further explore the proper role of communication surrogates, including medical interpreters, in reducing disparities for LEP patients taking warfarin anticoagulation, and the potential benefit from more simplified anticoagulation regimens that do not require intensive monitoring.

Disclosures

Daniel E. Singer has received research grants from Daiichi Sankyo and Johnson and Johnson and served as a consultant to Bayer Healthcare, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Johnson and Johnson, and Pfizer, all manufacturers of novel anticoagulants. The other authors have no conflicts to declare.

References

1. U.S. Census Bureau. Population estimates. Available at: http://www.census.gov. Accessed March 3, 2011.
2. Flores G. Language barriers to health care in the United States. N Engl J Med. 2006;355:229–231.
3. Bartlett G, Blais R, Tamblyn R, Clermont RJ, MacGibbon B. Impact of patient communication problems on the risk of preventable adverse events in acute care settings. CMAJ. 2008;178:1555–1562.
4. Johnstone MJ, Kanitsaki O. Culture, language, and patient safety: making the link. Int J Qual Health Care. 2006;18:383–388.
5. Divi C, Koss RG, Schmaltz SP, Loeb JM. Language proficiency and adverse events in US hospitals: a pilot study. Int J Qual Health Care. 2007;19:60–67.
6. Woloshin S, Bickell NA, Schwartz LM, Gany F, Welch HG. Language barriers in health care settings. J Gen Intern Med. 1995;273:724–728.
7. Cohen AL, Rivara F, Marcuse MK, McPhillips H, Davis R. Are language barriers associated with serious medical events in hospitalized pediatric patients? Pediatrics. 2005;116:575–579.
8. Gandhi TK, Burstin HR, Cook EF, Puopolo AL, Haas JS, Brennan TA, Bates DS. Drug complications in outpatients. J Gen Intern Med. 2000;15:149–154.
9. Wann LS, Curtis AB, January CT, Ellenbogen KA, Low EH, Estes NA III, Page RL, Ezekowitz MD, Slootwijk DJ, Jackman WM, Stevenson WG, Tracy CM, Fuster V, Ryden LE, Cannon DS, Le Heuzey JY, Crijns HJ, Olsson SB, Prystowsky EN, Halperin JL, Tamargo JL, Kay GN, Jacobs AK, Anderson JL, Albert N, Hochman JS, Buller CE, Kushner FG, Creager MA, Ohman EM, Ettinger SM, Guyton RA, Tarkington LG, Yancy CW. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;57:223–242.
10. Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ, Jenkins JS, Kline JA, Michaels AD, Thistedblaite P, Vedantham S, White RJ, Zierler BK. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation. 2011;123:1788–1830.
11. Choudhry NK, Soumerai SB, Normand SL, Ross-Degnan D, Laupacis A, Anderson GM. Warfarin prescribing in atrial fibrillation: the impact of physician, patient, and hospital characteristics. J Am Med. 2006;119:607–615.
12. Go AS, Hylek EM, Chang Y, Phillips KA, Renault LE, Capra AM, Jendvel NG, Selby JV, Singer DE. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA. 2003;290:2685–2692.
13. Singer DE, Chang Y, Fang MC, Borowsky LH, Pomeracki NK, Udaltsova N, Go AS. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009;151:297–305.
14. Schillinger D, Machtinger EL, Wang F, Palacios J, Rodriguez M, Bindman A. Language, literacy, and communication regarding medication in an anticoagulation clinic: a comparison of verbal vs. visual assessment. J Health Commun. 2006;11:651–664.
15. Machtinger EL, Wang F, Chen LL, Rodriguez M, Wu S, Schillinger D. A visual medication schedule to improve anticoagulation control: a randomized, controlled trial. J Comm J Qual Patient Saf. 2007;33:625–635.
16. Shalev V, Rogowski O, Shimron O, Sheinberg B, Shapiro I, Seligsohn U, Berliner S, Misgav M. The interval between prothrombin time tests and the quality of oral anticoagulants treatment in patients with chronic atrial fibrillation. Thromb Res. 2007;120:201–206.
17. Sarawate C, Sikirica MV, Willey VJ, Bullano MF, Hauch O. Monitoring anticoagulation in atrial fibrillation. J Thromb Thrombolysis. 2006;21:191–198.
18. Rose AJ, Hykle EM, Ozono A, Ash AS, Reisman JL, Berlowitz DR. Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the veterans affairs study to improve anticoagulation (VARIA). Circ Cardiovasc Qual Outcomes. 2011;4:22–29.
19. Fang MC, Chang Y, Hykle EM, Rosand J, Greenberg SM, Go AS, Singer DE. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004;147:745–752.
20. Singer DE, Chang Y, Fang MC, Borowsky LH, Pomeracki NK, Udaltsova N, Go AS. Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation? The ATRIA Study. Circ Cardiovasc Qual Outcomes. 2009;2:297–304.
21. Nalichowski R, Keogh D, Chueh HC, Murphy SN. Calculating the benefits of a research patient data repository. AMIA Annu Symp Proc. 2006;2006:1044.
22. Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, Lip GY, Manning WJ. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:544S–592S.
23. Houman Fekrazad M, Lopes RD, Stashenko GJ, Alexander JH, Garcia D. Treatment of venous thromboembolism: guidelines translated for the clinician. J Thromb Thrombolysis. 2009;28:270–275.
24. Rosendaal FR, Canneugieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69:236–239.
25. Deyo RA, Cherkin DC,iol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–619.
26. Higashi T, Wenger NS, Adams JL, Fung C, Roland M, McGlynn EA, Reeves D, Asch SM, Kerr EA, Shekelle PG. Relationship between number of medical conditions and quality of care. N Engl J Med. 2006;356:2496–2504.
27. Connolly SJ, Pogue J, Ekkelboom J, Fliker G, Comforpper FD, Franzoni MG, Healey JS, Yusuf S. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118:2029–2037.
28. Ansell JE, Hughes R. Evolving models of warfarin management: anticoagulation clinics, patient self-monitoring, and patient self-management. Am Heart J. 1996;132:1095–1100.
29. Bond CA, Raehl CL. Pharmacist-provided anticoagulation management in United States hospitals: death rates, length of stay, medicare charges, bleeding complications, and transfusions. Pharmacotherapy. 2004;24:953–963.
30. Chiouette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med. 1998;158:1641–1647.
31. Witt DM, Sadler MA, Shanahan RL, Mazzoli G, Tillman DJ. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest. 2005;127:1515–1522.
32. DuBard CA, Garrett J, Glicize Z. Effect of language on heart attack and stroke awareness among U.S. Hispanics. Am J Prev Med. 2006;30:189–196.
33. DuBard CA, Glicize Z. Language spoken and differences in health status, access to care, and receipt of preventive services among US Hispanics. Am J Public Health. 2008;98:2021–2028.
34. Flores G, Laws MB, Mayo SJ, Zuckerman B, Abreu M, Medina L, Hardt DJ. Errors in medical interpretation and their potential clinical consequences in pediatric encounters. Pediatrics. 2003;111:6–14.
35. Ku L, Flores G. Pay now or pay later: providing interpreter services in health care. Health Aff (Millwood). 2005;24:435–444.
36. Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnygina Y, Pan G, Halperin JL, Becker RC, Breithardt G, Hankey GJ, Hacke W, Nessel CC, Patel MR, Califf RM, Fox KA. Impact of global geospacial region on time in therapeutic range on warfarin anticoagulation therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc. 2013;2:e000067.
37. Fang MC, Machtinger EL, Wang F, Schillinger D. Health literacy and anticoagulation-related outcomes among patients taking warfarin. J Gen Intern Med. 2006;21:841–846.
38. Fang MC, Panguluri P, Machtinger EL, Schillinger D. Language, literacy, and characterization of stroke among patients taking warfarin for stroke prevention: implications for health communication. Patient Educ Couns. 2009;75:403–410.

39. Flores G. The impact of medical interpreter services on the quality of health care: a systematic review. Med Care Res Rev. 2005;62:255–299.

40. Baker DW, Hayes R, Fortier JP. Interpreter use and satisfaction with interpersonal aspects of care for Spanish-speaking patients. Med Care. 1998;36:1461–1470.

41. Schillinger D, Machtinger EL, Wang F, Chen LL, Win K, Palacios J, Rodriguez M, Bindman A. Language, literacy, and communication regarding medication in an anticoagulation clinic: are pictures better than words? In: Henriksen K, Battles JB, Marks ES, Lewin DI, eds. Advances in Patient Safety: From Research to Implementation (Volume 2: Concepts and Methodology). Rockville, MD: Agency for Healthcare Research and Quality; 2005:199–212.

42. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151.

43. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891.